R&D in UKsPharmaceuticalCompaniesGroup #3:Ahmed Abuiliazeed Diaa el BagouryOsama Hagag Mohamed Tarek
Presentation Structure:1. Overview.2. UK Pharma Now and Then.3. Problem Definition.4. Research Methodology.5. Challenges and Solutions
Overview● Competition with global market fueled theneed for more R&D activities and innovation.● R&D staff size, and R&D expenditures leadto more innovation in the company?● Level of innovation compared to the relativesize of the corporation.● Data sources:○ Loss of easy access to data due to large companymergers.○ Power of public data records
UK Pharma Industry Now:● Economic value of the industry
UK Pharma Industry Now:● R&D expenditures by sector
History● Number of new chemical entities per year
Problem Definition● UK falling behind competitors in thepharmaceutical industry○ Emerging economies○ Developed economies○ Lack of government investment● Solutions:○ Change business model○ Actions against counterfeit medicine○ Understanding global competition○ Preventive medicine through focus on R&D
Problem Definition● Companies with more focus on R&D moresuccessful?● Relation between innovation - company size.● How to quantify innovation?○ Papers○ Patents○ New drugs.● Company size measured through R&D○ R&D expenditure○ Number of researchers.
Research Methodology● The hypothesis of the research was basedon finding relationship between research andinnovation.● Claire decided to consider R&D expenditure,Number of scientists employed as researchindicators.● She also considered number of patents,research papers and new drugs produced asindicators for new innovations.
Data Resources & Classification1. Number of patents taken out of the company.2. Number of scientific papers published by its scientists.3. Number of drugs theyve launched on the marketbetween 1960 and 1969.4. Companies R&D expenditure.5. Number of scientists employed in R&D departments.
Data Resources & ClassificationThe data was collected from:● 6 pharmaceutical companies● Publications by the Department of trade, Department ofHealth.● Patent office● National Economic Development Office.● Reports from stockbrokers● Association of British Pharmaceutical Industry (ABPI).● Publications and good quality journalist Reports on theIndustry.
Additional Resources● Interviews with the R&D departments headsof the top 10 Pharmaceutical companies inUK.● survey with 1000 participants from thepharmaceutical industry.
Research Challenges& Solutions● Company merges moved archives around.● Difficult to get data from companies.● Some of the public data available was undera 30-year closure rule.● Public data sometimes not comprehensiveenough.Solution:● Extract information from ministry of healthcommittees.● Wait until data becomes available eventually
Lessons Learned● Keep an eye on the availability of data onthe subject, to not waste time or draw falseconclusions.● Raw data from the primary sources would bemost accurate.
References :1. Research and development in the UK pharmaceutical industry in the1960s.2. The UK Pharmaceutical Industry: Current Challenges and FutureSolutions3. Employment in the pharmaceutical industry in the UK4. Pharmaceutical innovation by the seven UK-owned pharmaceuticalcompanies (1964-1985)